NOVO-IPRAMIDE - LIQ 0.25MG/ML .25 MG
IPRATROPIUM BROMIDE : .25 MG · DIN 02210479 · NOVOPHARM LIMITED
Health Canada status: CANCELLED POST MARKET
What is NOVO-IPRAMIDE - LIQ 0.25MG/ML?
NOVO-IPRAMIDE - LIQ 0.25MG/ML .25 MG contains IPRATROPIUM BROMIDE : .25 MG. It is listed in the Health Canada Drug Product Database under DIN 02210479, held by NOVOPHARM LIMITED, supplied as SOLUTION for INHALATION administration. Health Canada currently lists it as cancelled post market, status dated 26-Oct-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02210479 |
|---|---|
| Brand name | NOVO-IPRAMIDE - LIQ 0.25MG/ML |
| Generic / active ingredient | IPRATROPIUM BROMIDE : .25 MG |
| Manufacturer | NOVOPHARM LIMITED |
| Strength | .25 MG |
| Dosage form | SOLUTION |
| Route of administration | INHALATION |
| Schedule | Prescription |
| ATC code | R03BB01 IPRATROPIUM BROMIDE |
| AHFS class | 24:24.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 26-Oct-2015 |
| Original market date | 1996-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02210479 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2210479 |
| Brand name | NOVO-IPRAMIDE - LIQ 0.25MG/ML |
| Active ingredient / INN | IPRATROPIUM BROMIDE : .25 MG |
| ATC code | R03BB01 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R03 |
| AHFS class | 24:24.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | NOVOPHARM LIMITED |
Which pack is which?
| Strength on the label | .25 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INHALATION |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code R03BB01 IPRATROPIUM BROMIDE. 8 of 30 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-IPRAVENT | 250 MCG | SOLUTION | AA PHARMA INC | MARKETED | DIN 02126222 |
| ATROVENT HFA | 20 MCG | METERED-DOSE AEROSOL | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED | DIN 02247686 |
| JAMP IPRATROPIUM HFA | 20 MCG | METERED-DOSE AEROSOL | JAMP PHARMA CORPORATION | MARKETED | DIN 02542587 |
| PMS-IPRATROPIUM | 125 MCG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02231135 |
| PMS-IPRATROPIUM | 21 MCG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02239627 |
| PMS-IPRATROPIUM | 250 MCG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02231244 |
| PMS-IPRATROPIUM | 250 MCG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02231245 |
| TEVA-IPRATROPIUM STERINEBS | 250 MCG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02216221 |
| APO-IPRAVENT STERULES | 125 MCG | SOLUTION | APOTEX INC | CANCELLED POST MARKET | DIN 02243827 |
| APO-IPRAVENT STERULES | 250 MCG | SOLUTION | APOTEX INC | CANCELLED POST MARKET | DIN 02231494 |
Who else supplies IPRATROPIUM BROMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IPRATROPIUM BROMIDE appears in 80 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.